Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
Public ClinicalTrials.gov record NCT05633407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).
Study identification
- NCT ID
- NCT05633407
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2022 (Actual)
- Primary completion
- Apr 18, 2024 (Actual)
- Completion
- Apr 18, 2024 (Actual)
- Last update posted
- May 23, 2025
2022 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego Sulpizio Cardiovascular Center | La Jolla | California | 92037 | — |
| Stanford Movement Disorder Center | Palo Alto | California | 94304 | — |
| Northshore University Health System | Glenview | Illinois | 60026 | — |
| Johns Hopkins University | Baltimore | Maryland | 21224 | — |
| Harvard Medical School, Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Vandetbilt University Medical Center / Clinical Research Center | Nashville | Tennessee | 37232 | — |
| Apex Trials Croup, LLC | Fort Worth | Texas | 76132 | — |
| Texas Institute of Cardiology | McKinney | Texas | 75071 | — |
| Pioneer Clinical Research | Rosharon | Texas | 77583 | — |
| Metrodora Institute | West Valley City | Utah | 84119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05633407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05633407 live on ClinicalTrials.gov.